Professor of Medicine and Director of the Centre for Regenerative Medicine at Massachussetts General Hospital, David Scadden is also one of the architects and scientific directors of the Harvard Stem Cell Institute. As a hematologist and oncologist, he is seeking to develop the therapeutic potential of stem cells. He kindly agreed to talk to Gene Therapy about the his work with the institute and his thoughts on the field of stem cell research.
Gene Therapy (GT):
Stem cells are a controversial issue and yet hold enormous hope for regenerative medicine, which is what the institute that you run works on. Could you describe the missions of your institute?
David Scadden (DS): The Harvard Stem Cell institute came about from an awareness that a lot of people were interested in working in this field but didn't really have an internal structure allowing interactions at more than just the national and international meetings. So, we needed a central organizing theme that would allow us to accelerate the field through crosstalk between people focussed on different disciplines and disease entities who have a lot of shared technologies and potentially shared mechanisms. Doing this would also enable us to put together some core technology that could encourage gene investigators to come into the field, and potentially raise sufficient funds for junior investigators who might be concerned about coming into a setting where the traditional engine of research is jeapordized, with the absence of federal government participation. That discussion happened among a number of us, and then Doug Melton and I worked together to try to form some cohesion around the theme. The leadership of the university affiliated hospitals has been tremendous and we have been able to get a lot of traction in terms of building a community, developing some of the mechanisms by which we have the intellectual exchange we were hoping for, as well as having support to create sources of funding for different innovative projects and for investigators entering the field.
GT: How is your institute funded?
DS:
We have some seed funding from Harvard and the affiliated hospitals. We have also had really a great response from the philanthropic community associated with these institutions. People recognize that this is a generally three-legged stool with one of the legs now missing, with the federal government out of the mix. One of the other legs, industry, is slow to activate around this issue. The last leg is philanthropy, which is really our main driver and people have really responded to that need and we've had substantial success in that regard.
GT: Could you comment on the history of this field, which is relatively new, although adult stem cells have been developed for transplants for a number of years now.
One of the areas I've always been interested in is adult stem cells and the hematopoietic system. I came into this as a hematologist/ oncologist particularly interested in rebuilding immune function. My interest has been in people with HIV disease and hemalogic and oncologic complications thereof, to see if we could rebuild immunity, particularly hoping to engage the field of gene therapy to potentially alter the sensitivity of the immune system to the virus. Over the course of the last 7 years or so, the field of embryonic stem cells recognized that a lot of other adult stem cell pools have been identified. Doug Melton came at this from the perspective of a developmental biologist, focused on the embryology of xenopus, and because of his experiences with his own family, he recognized the need to get novel therapies to treat diseases like diabetes. He decided to convert his program into one that could exploit embryonic stem cells, as a way to generate tissues that could potentially replace damaged adult tissues. So he came at it as a developmental biologist, working on embryonic cells; I came at it with a therapist's perspective, working on adult stem cells. We represented the bookends of the field and there has been a tremendous amount of crosstalk and opportunity for synergy between these ends. We have a wide range of laboratories that focus on many different aspects, extending from both of those different poles.
GT: That raises an interesting point, that adult stem cells are less pluripotent than embryonic stem cells but still there's a great deal to be learned about how cells differentiate and what controls that differentiation process. What do you think needs to be discovered in this regard and how should we approach this complex problem of differentiation? DS: Equally important is the issue of gene differentiation and whether or not one can understand the complex process that must occur for nuclear transfer to be successful. How a somatic cell nucleus can be so substantially altered that it can actually be reinduced to acquire a pluripotent state and result in a Dolly, for example. And whether or not by comparing the embryonic and the adult stem cell, and looking at different stages of differentiation within the embryonic system, we can start to sift out some of the molecular mechanisms by which that occurs and selectively target them. We certainly know, for example, that the egg nucleus is capable of altering somatic cells in a dramatic way. It's all biochemistry; it's just a matter of sorting out what the biochemistry is.
GT: What kind of technologies will we need in the future in order to do this? DS: I think there are a number of relatively simple technologies that need to be accomplished. We need to establish cell lines, for example, INTERVIEW that can be armed with indicators to tell us when specific molecular events are occuring, such as an embryonic stem cell acquiring a germline specificity, undergoing mesodermal, endodermal and ectodermal fate determination. Similarly, when embryonic genes are on, we need to be able to do chemical screens so we can identify drugs that have the capacity to induce specific changes -that would be a very valuable tool. We need to identify the stem cell population in adult tissues that are thought to be there but are still very poorly described in most tissue systems. And, defining a lot of the epigenetic phenomena associated with lineage commitment would be critical.
GT: Speaking of epigenetic phenomena, when nuclei are taken out of a skin cell, for example, and placed into a cell that might develop into an embryo, do you envision that the cell loses the histone code associated with those genes and that it acquires a new phenotype, or is something carried over in that kind of cloning? DS: I think evidence would suggest that it's an imperfect recreation, or reversal of the epigenetic memory of differentiation, because it doesn't appear that the cloned embryos are normal. There's a persistant developmental alteration; most of the organisms that have been created with that technology appear to have phenotypic changes. So I suspect a lot of the reprogramming is nearly complete but still imperfect.
GT: It's an interesting problem. In one sense, when a cell becomes a liver cell, for example, it has an epigenetic memory as you point out, yet when you take that nucleus out and put it into another cell type, at least the majority of that is lost.
It's a fantastic opportunity to really sort that out, now that we're getting some of the tools to sort it out with some efficiency. It's one of the areas that's very rich with opportunity, because if one can understand the basis for it, the potential to manipulate it would be something really quite powerful.
GT: I guess we don't even really have good tools to understand yet how histones are being manipulated by the cell, or how they remain in place in order to govern gene expression.
Technologies are rapidly developing in that area. Recent publications about being able to do genome-wide analyses of epigenetic alterations are something that will greatly accelerate the rate of discovery.
GT: What is the biggest scientific question that interests you, and if you weren't constrained by technology or money or politics, how would you envision approaching this question? DS: I am at heart a therapist and most interested in bringing some of the basic biology to a context where it could really have an impact on people. Owing to my history working with adult stem cells, and the now growing appreciation in the field that there are permanent progenitor stem cell populations in most adult tissues, I think one of the great opportunities is to understand the hard wiring of those cells in the context of the tissues; what makes them function in a very different way in the adult -where they seem to serve mainly a maintenance function -than they do early on in development, where they clearly are capable of generating new tissue. If one could understand what it is that constrains the stem cell pool from recreating that process, could one target that? Could one develop either pharmacologic or genetic tools that would allow a permanent population of cells persistant in adult tissues to return to functions that would allow for restoration of tissue rather than just scar, in what seems to be a fairly dysfunctional way.
GT: That's an exciting idea. In fact, it's sort of a teleological question. Almost every tissue in the body regenerates; some tissues are more capable of doing this than others, or at least do it more rapidly. So, the notion is whether there are adult stem cells that can be put into a state in which they can be used broadly.
Exactly. There are cells in tissues that were previously thought to be essentially inert in adulthood, like the adult brain, but we now recognize populations of cells that can have robust proliferation ex vivo and yet in settings of injury do very little in terms of being able to induce neoneurogenesis. What are the constraints of that environment and are those surmountable to potentially change that response? That is something that I think the field could focus on.
GT: In South Korea in particular, there's been a tremendous push in the area of stem cell research, and Asia in general seems to be capturing the lead because funds are available and there are no political restraints -Is America really in danger of losing the lead in stem cell research? DS: I have to say, that to me is clearly the call. That is happening and has already substantially happened. I think there are still tremendous advantages to the structure in which research is conducted here. I think that our history of innovation is such that we will continue to contribute, but I do think there has been an impact on the willingness of junior people to get involved in the field and the ability of senior people to move into what is an area of great opportunity given embryonic stem cells; that has an impact now and certainly will have an impact in the future. That said, I think it's fantastic that there other countries involved and the competition only helps the field in general. So, I think it's a great thing, they've done tremendous work, that's a huge breakthrough. I applaud that and I wish that we had similar foresight in the scientific leadership on a policy level that would allow us to be fully participating colleagues with them. I regret the fact that our science is now in some ways dictated by ideologies that are political and not oriented towards science.
GT: Gene therapy is an older field, although the first patient was only treated in 1990. There was a tremendous amount of hype about the promise of therapeutic gene transfer and while the field has struggled to create technologies that will be useful in patients, I think it's been perceived as being slow to reach its promise. Transplantation, however, took at least 30 years to reach its promise and required some substantial breakthroughs in terms of immune suppression and so on. How do you feel about gene therapy today? Do you think this is a viable field and what contributions can gene therapy make?
DS: I think, as you point out, the field of stem cell transplant was very slow and it was really the parallel development of immunology that allowed it to develop and it was only through the synergistic interaction of those fields that we have the ability to save lives with transplants today. I think, similarly, that in some ways gene therapy was ahead of the curve and stem cell biology will be a very important partner; stem cell therapy and gene therapy are hand in glove.
Stem cell therapy's successes will depend on gene transfer technologies that have been developed by the gene therapy investigative community.
I do think the unfortunate lessons of controlling expectations in the gene therapy world will continue to be a problem. I've certainly been aware of the honeymoon phase in stem cell biology, but I'm sure we're going to have the same pendulum swing, unless there's a rapid payoff, particularly when taxpayers in California are looking at adding $3billion of debt. That's only the beginning of this backlash, which has the potential of being very damaging to the field unless we come up with some very early hits. I think part of the problem is that scientists believe in the potential, but I don't think they are really communicating the complexity of the problems ahead. I'm hoping that one thing that may help the stem cell world is that in addition to using the cells themselves as therapy, there is an opportunity to use the cells as ways of identifying good drugs.
GT: Related to training, what should we be encouraging young scientists to do in biology today. If you were going to give advice to a new graduate student, for example, what would you tell them about the future of this field? DS: I encourage students to try to become bilingual. I think it's through the collision of different disciplines that the greatest opportunities for discovery exist. I want students who work with me to go off and do a post doc in a very different field. While I want them to build on what they've learned, I think if they just simply extend it they're missing a great opportunity. They should have a chance to really go out and explore what would be a very different way of looking at a problem through learning a new discipline. It creates a bit of internal distress for people to do it, but I think in the long run it serves them well as they'll be able to provide a creative spark through being able to see things through a binocular lens.
GT: I think it is a great idea, even though it is stressful and it runs in conflict with CV building.
You're absolutely right. Promotion committees want to be able to describe people in a one-line soundbite, but the field is not best served by that kind of narrow focus. Within the stem cell institute there are a number of different centres. Harvard is this odd confederation of independent hospitals associated with the university and each of those has a very signature group of stem cell investigators. At the Mass General, where I am, we have the opportunity to grow because our institution is funding and giving us space for a center for regenerative medicine, so we decided to build in technologies that are very different from the usual cell biology that would accompany this field. We have bioengineers in here, we have computational biologists, imaging people and those who are interested in work relating to the fundamental molecular biology. We're trying to get a number of people who view things through different worlds, from computer science or engineering to biology and biochemistry, into one space so that we can be a part of each other's creative process, to extend beyond the margins of our own disciplines. DS: That's a great point. In general, I think we tend to view ourselves as the lucky recipients of the largesse of the public. We have the opportunity to do this work, but unfortunately it hasn't come with a commensurate sense of responsibility and accountability, to give information and let people know why it's important to make this investment and what they're investing in. It seems to be nobody's job to do that within our usual structures of science. I think societies are very important for that, at organizing the message so that there can be materials generated and provided to policy makers and thought leaders outside the scientific community. I would hope between societies there would be a chance to develop strategies to put together cohesive educational platforms that can go out to the public. I think that fortunately with access to electronic materials now, we can do that a little bit more readily. We need to have very informative, easy to access websites that are dedicated to the public viewer as well as the scientist.
GT:
GT: I absolutely agree with that. The concern we have of course is that active engagement and education is very expensive. There's a special group of people out there who know how to do this, but the associated costs make expert help difficult to underwrite.
DS:
There's never a line item on a budget for this, but it is one of the things that in the long view is one of the most important things for our own self-interest as well as the interest of the public. One of the things we've found from talking to people in the community is that there are a lot of people interested in helping. We don't know exactly how to engage them but we've certainly found that there are people in the advertizing and communication worlds who really want to contribute to this. The problem is that they need to get their content from scientists, who are generally struggling with grant deadlines or getting papers out, who don't really want to spend the time. We need to find ways to productively partner up with people like that.
GT: All of us think about the future and measure our lives in 5-year blocks. If things go well in this arena, where do you suppose we'll be in 5 or 10 years? DS: I think there are a couple of areas where there's some low-hanging fruit. One is that in the embryonic stem cell world we probably will be able to at least create diseasespecific cell lines that will allow some better understanding of some complex genetic disorders. So, we will be able to potentially make neurons that may be representative of the neurons that are damaged in ALS and start to understand a little bit about those kinds of processes.
I think we may learn how to guide those cells to become particular cell types. We know they can pretty readily become cardiomyocytes and there may be ways in which they can be engaged to become things like insulin-producing cells. If we can accomplish either of those things with efficiency, then they do offer the potential, certainly in terms of the insulin-producing cell, of possibly being a source of transplantable tissue. Something that is producing at a distance, in an endocrine manner, is very appealing, so I would think that diabetes is one of the most exciting potential targets for embryonic stem cell work.
I really do think that we'll begin to learn about endogenous stem cells, and start to learn about how to potentially manipulate them. So I am optimistic that we will end up using agents that may already be approved drugs but have never been viewed from the perspective of how they might affect stem cells.
GT: Thank you very much.
This interview was conducted by Joseph Glorioso and Jenny Jacoby.
